¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"squamous cell carcinoma antigen"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • diphasic antigen
    ÀÌ»ó(ì£ßÓ)Ç׿ø
  • early antigen
    ÃʱâÇ׿ø
  • excretory-secretory antigen
    ¹è¼³ºÐºñÇ׿ø
  • egg antigen
    Ãæ¶õÇ׿ø
  • envelope antigen
    ¿ÜÇÇÇ׿ø
  • environmental antigen
    ȯ°æÇ׿ø
  • epithelial membrane antigen
    »óÇǸ·Ç׿ø
  • fimbrial antigen
    °¡´ÂÅÐÇ׿ø
  • flagellar antigen
    Æí¸ðÇ׿ø
  • formalinized antigen
    Æ÷¸£¸»¸°Ã³¸®Ç׿ø
  • functional antigen
    ±â´ÉÇ׿ø
  • granulocyte-erythrocyte antigen
    °ú¸³±¸ÀûÇ÷±¸Ç׿ø
  • granulocyte-monocyte antigen
    °ú¸³±¸´ÜÇÙ±¸Ç׿ø
  • granulocyte-specific antigen
    °ú¸³±¸Æ¯ÀÌÇ׿ø
  • group antigen
    ¹«¸®Ç׿ø, ±ºÇ׿ø
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • envelope antigen
    ¿ÜÇÇÇ׿ø
  • environmental antigen
    ȯ°æÇ׿ø
  • excretory-secretory antigen
    ºÐºñ¹è¼³Ç׿ø
  • fimbrial antigen
    °¡´ÂÅÐÇ׿ø
  • flagellar antigen
    ±äÅÐÇ׿ø
  • formalinized antigen
    Æ÷¸£¸»¸°Ã³¸®Ç׿ø
  • functional antigen
    ±â´ÉÇ׿ø
  • granulocyte-erythrocyte antigen
    °ú¸³±¸ÀûÇ÷±¸Ç׿ø
  • granulocyte-monocyte antigen
    °ú¸³±¸´ÜÇÙ±¸Ç׿ø
  • granulocyte-specific antigen
    °ú¸³±¸Æ¯ÀÌÇ׿ø
  • group antigen
    ±ºÇ׿ø
  • group-specific antigen
    ±ºÆ¯ÀÌÇ׿ø
  • hepatitis B core antigen
    ºñÇü°£¿°ÇÙ½ÉÇ׿ø
  • hepatitis B surface antigen
    ºñÇü°£¿°Ç¥¸éÇ׿ø
  • heterogenetic antigen
    (¢¡heterophil antigen) ÀÌÁ¾Ä£È­Ç׿ø
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • Pr antigen
    Pr Ç׿ø
  • Qa antigen
    QaÇ׿ø (H-2º¹ÇÕüÀÇ)
  • Rh(D) antigen
    Rh(D) Ç׿ø
  • Ro antigen
    RoÇ׿ø
  • Ro antigen
    Ro Ç׿ø
  • Roger antigen
    ·ÎÀúÇ׿ø
  • Scianna antigen
    ½Ã¾Æ³ªÇ׿ø
  • Sda antigen
    Sda Ç׿ø
  • Sp (Pr) antigen
    Sp(Pr) Ç׿ø
  • T dependent antigen
    TÀÇÁ¸¼ºÇ׿ø
  • Tac antigen
    Tac Ç׿ø
  • Thy-1 antigen
    Thy-1Ç׿ø
  • U antigen
    U Ç׿ø
  • V antigen
    V Ç׿ø
  • Vi antigen
    ViÇ׿ø.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • bartholin gland carcinoma
    ¹Ù¸£Å縰¼±¾Ï
  • bladder carcinoma
    ¹æ±¤¾ÏÁ¾
  • breast carcinoma
    À¯¹æ¾Ï
  • breast,carcinoma
    ¾ÏÁ¾(äßðþ)
  • breast,carcinoma colloid or mucinous
    Á¡¾×¼º (ïÄäûàõ)
  • breast,carcinoma cystosarcoma phyllodes
    ¿±»ó ³¶¼º À°Á¾(ç¨ßÒÒ¥àõë¿ðþ)
  • breast,carcinoma ductal
    °ü»ó(ηßÒ)
  • breast,carcinoma en cuirasse
    en cuirasse ¾ÏÁ¾(¡­äßðþ)
  • breast,carcinoma galactocele
    À¯¼± ³¶Á¾ (êáàÍÒ¥ðþ)
  • breast,carcinoma infiltrating duct
    ħÀ±¼º °ü»ó (öÙëÈàõηßÒ)
  • breast,carcinoma intraductal
    °ü³»(ηҮ)
  • breast,carcinoma inverted nipples
    ÇÔ¸ôÀ¯µÎ (ùèÙÒêáÔé)
  • breast,carcinoma lobular
    ¼Ò¿± (á³ç¨)
  • breast,carcinoma lobular, in situ
    ¼Ò¿±¼º, ºñħÀ±¼º
  • breast,carcinoma mammography
    À¯¹æ Á¶¿µ¼ú (êáÛ®ðãç¯âú)
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • Goblet cell
    ¼úÀܼ¼Æ÷
    [¿¾ ¿ë¾î] ¹è»ó¼¼Æ÷
  • Neurosensory epithelial cell
    ½Å°æ°¨°¢»óÇǼ¼Æ÷
    [¿¾ ¿ë¾î] ½Å°æ°¨°¢»óÇǼ¼Æ÷
  • Ganglion cell layer
    ½Å°æÀý¼¼Æ÷Ãþ
    [¿¾ ¿ë¾î] ½Å°æÀý¼¼Æ÷Ãþ
  • Satellite cell
    ½Å°æÀý¾Æ±³¼¼Æ÷
    [¿¾ ¿ë¾î] À§¼º¼¼Æ÷
  • Satellite cell
    ½Å°æÀý¾Æ±³¼¼Æ÷ [À§¼º¼¼Æ÷]
    [¿¾ ¿ë¾î] ½Å°æÀý±³¼¼Æ÷
  • Satellite cell
    ½Å°æÀý¾Æ±³¼¼Æ÷ [À§¼º¼¼Æ÷]
    [¿¾ ¿ë¾î] À§¼º¼¼Æ÷
  • Cardiac muscle cell
    ½ÉÀå±ÙÀ°¼¼Æ÷
    [¿¾ ¿ë¾î] ½É±Ù¼¼Æ÷
  • Glial cell
    ¾Æ±³¼¼Æ÷
    [¿¾ ¿ë¾î] ±³¼¼Æ÷
  • Glial cell process
    ¾Æ±³¼¼Æ÷µ¹±â
    [¿¾ ¿ë¾î] ±³¼¼Æ÷µ¹±â
  • Glial cell body
    ¾Æ±³¼¼Æ÷ü
    [¿¾ ¿ë¾î] ±³¼¼Æ÷ü
  • Ameboid cell
    ¾Æ¸Þ¹Ù¸ð¾ç¼¼Æ÷
    [¿¾ ¿ë¾î] ¾Æ¸Þ¹Ù¾ç¼¼Æ÷
  • Dark cell
    ¾îµÎ¿î¼¼Æ÷
    [¿¾ ¿ë¾î] ¾Ï¼¼Æ÷
  • Dark cell
    ¾îµÎ¿î¼¼Æ÷
    [¿¾ ¿ë¾î] ¾ÏÁÖ¼¼Æ÷
  • Trophoblastic giant cell
    ¿µ¾ç¸·°Å´ë¼¼Æ÷
    [¿¾ ¿ë¾î] °Å´ë¿µ¾ç¸·¼¼Æ÷
  • Primordial germ cell
    ¿ø½ÃÁ¾ÀÚ¼¼Æ÷
    [¿¾ ¿ë¾î] ¿ø±âÁ¾(¹è)¼¼Æ÷
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • immune competent cell
    ¸é¿ª Àû°Ý ¼¼Æ÷(Øóæ¹îêÌ«á¬øà)
  • immunocompetent cell
    ¸é¿ªÀû°Ý¼¼Æ÷(Øóæ¹îêÌ«á¬øà)
  • immunologically competent cell
    ¸é¿ª Àû°Ý ¼¼Æ÷(Øóæ¹îêÌ«á¬øà)
  • inducer T cell
    À¯µµÀÚ(ë¯Óôí­) T¼¼Æ÷(á¬øà)
  • interstitial cell hormone
    °£Áú¼¼Æ÷(Êàòõá¬øà) È£¸£¸ó
  • interstitial cell-stimulating hormone
    °£Áú¼¼Æ÷(Êàòõá¬øà)ÀÚ±Ø(í©Ð½) È£¸£¸ó
  • isologous cell line
    µ¿Á¾¼¼Æ÷ÁÖ(ÔÒðúá¬øàñ»)
  • K cell
    K ¼¼Æ÷(á¬øà)
  • killer cell
    »ì¼¼Æ÷(ß¯á¬øà)
  • memory cell
    ±â¾ï¼¼Æ÷(ÑÀåãá¬øà)
  • natural killer cell
    ÀÚ¿¬ »ì¼¼Æ÷(í»æÔß¯á¬øà)
  • NK cell
    NK ¼¼Æ÷(á¬øà)
  • nonpermissive cell
    ºñÇã¿ë ¼¼Æ÷(ÞªúÉé»á¬øà)
  • null cell
    ¹«Ç¥Áö¼¼Æ÷(Ùíøúò½á¬øà)
  • permanent cell strain
    ¿µ±¸¼¼Æ÷ÁÖ(çµÎùá¬øàñ»)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 8
AFP Alpha(¥á) Feto-Protein [HP 1826, 1858, 1859, 2265]
  ; Oncofetal Antigens
 &nbs...
BCC Basal Cell Carcinoma
BCC basal-cell carcinoma; biliary cholesterol concentration; birth control clinic
ECC electrocorticogram, electrocorticography; electronic claim capture; embryonal cell carcinoma; emerge...
HMCCMP human mammary carcinoma cell membrane proteinase
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 8
TCC Transitional Cell Carcinoma
ACC Acinic cell carcinoma
BCC Basal Cell Carcinoma
CCC Clear cell carcinoma
LCC Large Cell Carcinoma
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • embryonal carcinoma
    ¹è¾Æ¼º ¾ÏÁ¾
    °íȯ¿¡ »ý±â´Â °°Àº Á¾·ùÀÇ ¾ÏÁ¾º¸´Ù´Â ´ú ÈçÈ÷ ³­¼Ò¿¡ ¹ß»ýÇÏ°í ¾î¸°ÀÌ¿Í ÀþÀº ¿©¼º¿¡ È£¹ßÇÑ´Ù. Á¶Á÷ÇÐÀûÀ¸·Î ¹Ì¼º¼÷ »óÇÇ ¼¼Æ÷µéÀÌ ¹Ì¸¸¼º ¶Ç´Â ¼±»ó ÇüÅ·Π¹è¿­µÈ´Ù. À¶ÇÕ ¼¼Æ÷ ¿µ¾ç¸· °Å´ë ¼¼Æ÷°¡ ´ëºÎºÐ ÃâÇöÇÏ¿© HCG¿¡ ¾ç¼ºÀ̰í Å»ý±â ¾Ï ¼¼Æ÷´Â ¾ËÆÄ ÅÂ¾Æ ´Ü¹é¿¡ ¾ç¼ºÀÌ´Ù.
  • endometrial carcinoma
    Àڱà ³»¸· ¾ÏÁ¾
    ÇϳªÀÇ ±ºÀº Áö¼ÓÀûÀÎ ¿¡½ºÆ®·Î°Õ Àڱذú Àڱ󻸷 °úÇü¼ºÀÇ ¹è°æ¿¡¼­ ¹ß»ýÇÑ´Ù´Â °ÍÀÌ´Ù. Àڱ󻸷 °úÇü¼º°ú ¾ÏÁ¾Àº ºñ¸¸°ú ¹«¹è¶õ ÁÖ±â¿Íµµ À¯°üÇÏ´Ù. ÀÌ·¯ÇÑ ÀÎÀÚµé°ú ¿¬°üµÇ¾î ¹ß»ýÇÑ ³»¸· ¾ÏÀº ºÐÈ­°¡ ÁÁÀº °æÇâÀÌ ÀÖ°í ÇüÅÂÇÐÀûÀ¸·Î Á¤»ó ³»¸·¼±°ú À¯»çÇÑ "Àڱ󻸷¾ç
  • epithelial carcinoma
    »óÇÇ ¾ÏÁ¾
  • infiltrating duct breast carcinoma
    ħÀ±¼º °ü»ó À¯¹æ ¾Ï
  • intraductal carcinoma
    ¼±°ü³» ¾Ï
  • invasive carcinoma
    ħ½À¼º ¾ÏÁ¾
  • inverted nipples breast carcinoma
    ÇÔ¸ô À¯µÎ À¯¹æ ¾Ï
  • laryngeal carcinoma
    ÈĵξÏ
    Èĵο¡ ¹ß»ýÇÏ´Â ¾Ï. 95 % ÀÌ»óÀÌ Á¶Á÷ÇÐÀûÀ¸·Î ÆíÆò »óÇǾÏ
  • latent carcinoma
    ÀáÀ缺 ¾Ï
    ºÐ¸íÈ÷ ¾ÏÀÌÁö¸¸ ÀÓ»óÀûÀ¸·Î Áõ»óÀÌ ¾øÀ¸¸ç, ¿¬·É Áõ°¡ ½Ã ÇÔ²² Áõ°¡ÇÑ´Ù.
  • lobular breast carcinoma in situ
    ¼Ò¿±¼º, ºñħÀ±¼º À¯¹æ ¾Ï
  • medullary carcinoma
    ¼öÁú¼º ¾ÏÁ¾
  • mucinous breast carcinoma
    Á¡¾×¼º À¯¹æ ¾Ï
  • nonseminomatous testicular carcinoma
    ºñÁ¤»ó ÇÇÁ¾¼º °íȯ ¾Ï
  • palate carcinoma
    ±¸°³ ¾Ï
    ±¸°³ºÎ¿¡ ¹ß»ýÇÑ ¾Ï.
  • papillary carcinoma
    À¯µÎ¾Ï, À¯µÎ»ó ¾ÏÁ¾
    1. À¯µÎ ¸ð¾çÀÇ Áõ½ÄÀÌ ÀÖ´Â ¾ÏÁ¾. 2. À¯µÎ»ó ¼ºÀåÀ» ÇÏ´Â ¸ðµç °©»ó¼± Á¾¾çÀ» ÀÌ ¹üÁÖ¿¡ ³Ö´Â´Ù. ¼ø¼öÈ÷ À¯µÎ»ó ±¸Á¶¸¸ ÀÖ´Â °ÍÀÌ ¾Æ´Ï¶ó ¿©Æ÷»ó ±¸Á¶°¡ ¼¯¿© Àֱ⵵ ÇÏ´Ù. ´ëºÎºÐÀÇ À¯µÎ»ó ¾ÏÁ¾Àº ¹«Å뼺ÀÌ°í ¿¹Èİ¡ ¸Å¿ì ÁÁ´Ù. 10-20%¿¡¼­ ±¹¼Ò ¸²ÇÁÀýÀÇ ÀüÀÌ·Î °æºÎ ¸²ÇÁÀý Á¾´ë°¡ ù Áõ»óÀÌ´Ù. À¯µÎ»ó ¾ÏÁ¾Àº Àü °©»ó¼± ¾ÏÁ¾ÀÇ 75-85%·Î °©»ó¼± ¾ÏÁ¾ Áß °¡Àå ÈçÇϸç 20´ë ³»Áö 60´ë¿¡ È£¹ßÇϰí 40¼¼ ÀÌÇÏ¿¡¼­´Â 80%ÀÇ ¾ÏÁ¾ÀÌ À¯µÎ»óÀÌ´Ù. ¿©¼ºÀÌ 2-3¹è ¸¹´Ù.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
carcinoma, medullary A carcinoma composed mainly of epithelial elements with little or no stroma. Medullary carcinomas of the breast constitute 5%-7% of all mammary carcinomas; medullary carcinomas of the thyroid comprise 3%-10% of all thyroid malignancies.
(12 Dec 1998)
carcinoma, mucoepidermoid A tumour of both low- and high-grade malignancy. The low-grade grow slowly, appear in any age group, and are readily cured by excision. The high-grade behave aggressively, widely infiltrate the salivary gland and produce lymph node and distant metastases. Mucoepidermoid carcinomas account for about 21% of the malignant tumours of the parotid gland and 10% of the sublingual gland. They are the most common malignant tumour of the parotid.
(12 Dec 1998)
carcinoma myxomatodes An obsolete term for a form of colloid cancer in which there is myxomatous metaplasia of the cellular fibrous stroma.
(05 Mar 2000)
carcinoma, neuroendocrine A group of carcinomas which share a characteristic morphology, often being composed of clusters and trabecular sheets of round "blue cells", granular chromatin, and an attenuated rim of poorly demarcated cytoplasm. Neuroendocrine tumours include carcinoids, small ("oat") cell carcinomas, medullary carcinoma of the thyroid, merkel cell tumour, cutaneous neuroendocrine carcinoma, pancreatic islet cell tumours, and pheochromocytoma. Neurosecretory granules are found within the tumour cells.
(12 Dec 1998)
carcinoma, papillary A malignant neoplasm characterised by the formation of numerous, irregular, finger-like projections of fibrous stroma that is covered with a surface layer of neoplastic epithelial cells.
(12 Dec 1998)
carcinoma, papillary, follicular A thyroid neoplasm of mixed papillary and follicular arrangement. Its biological behaviour and prognosis is the same as that of a papillary adenocarcinoma of the thyroid.
(12 Dec 1998)
carcinoma simplex An obsolete term for any form of carcinoma in which the relative proportions of stroma and neoplastic epithelial cells are not unusual, i.e., stromal elements are not comparatively abundant, nor are they reduced in amount or lacking; an obsolete term for a carcinoma lacking any identifiable microscopic pattern, such as glandular structure.
(05 Mar 2000)
carcinoma, skin appendage A malignant tumour of the skin appendages, which include the hair, nails, sebaceous glands, sweat glands, and the mammary glands.
(12 Dec 1998)
carcinoma, verrucous A variant of well-differentiated epidermoid carcinoma that is most common in the oral cavity, but also occurs in the larynx, nasal cavity, oesophagus, penis, anorectal region, vulva, vagina, uterine cervix, and skin, especially on the sole of the foot. Most intraoral cases occur in elderly male abusers of smokeless tobacco. The treatment is surgical resection. Radiotherapy is not indicated, as up to 30% treated with radiation become highly aggressive within six months.
(12 Dec 1998)
V-2 carcinoma <tumour> A transplantable, highly malignant carcinoma of experimental animals that developed as a result of malignant change in a virus-induced papilloma of a domestic rabbit.
(05 Mar 2000)
gallbladder carcinoma <radiology> Females (80%), peak age 60 - 70 years of age, associated with, gallstones (60-90%), porcelain gall bladder
(12 Dec 1998)
gastric carcinoma <radiology> 3rd most common GI malignancy (after colorectal and pancreas), 95% adenocarcinoma (rarely squamous cell or adenoacanthoma), predisposing factors: pernicious anaemia (2X risk), chronic atrophic gastritis, adenomatous and villous polyp (7-27% are malignant), gastrojejunostomy types: polypoid / fungating, ulcerating / penetrating (70%), infiltrating / scirrous = linitis plastica, increase in fibrous tissue; aperistalsis; rigidity, superficial spreading carcinoma, confined to mucosa/submucosa; 95% 5-year survival, patch of nodularity; little loss of elasticity location: 60% lesser curvature, 30% GE junction, 10% greater curvature probability of malignancy of an ulcer: fundus 90%, greater curvature 70%, lesser curvature 10-15%
(12 Dec 1998)
papillary carcinoma <tumour> A malignant neoplasm characterised by the formation of numerous, irregular, finger-like projections of fibrous stroma that is covered with a surface layer of neoplastic epithelial cells.
(05 Mar 2000)
verrucous carcinoma <tumour> A well differentiated papillary squamous cell carcinoma, especially of the oral cavity or penis, that may invade locally but rarely metastasizes; the usual cytologic features of malignancy are absent.
(05 Mar 2000)
villous carcinoma <tumour> A form of carcinoma in which there are numerous, closely packed, papillary projections of neoplastic epithelial tissue.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 8
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 8
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 8
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 8
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 8
ÅëÇÕ°Ë»ö ¿Ï·á